Researchers are calling for changes to the treatment of chronic pain, with more routine screening for depression and anxiety ...

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a clinical-stage pharmaceutical company focused on developing therapies for neurological and neuropsychiatric disorders, today announced the successful ...

U.S. researchers said Wednesday they have reproduced the pain-relieving effects of cannabis with a synthesized compound that ...

Strategic anti-inflammatory food choices target underlying inflammatory pathways to reduce chronic pain intensity and ...

VIP36, a new CB1 agonist, targets a cryptic pocket to provide analgesia for chronic pain while minimizing side effects and ...

Terpenes from cannabis may relieve chronic pain without THC’s psychoactive effects. Researchers found that certain terpenes ...

Among 347,468 individuals who had lived with persistent pain for over 3 months, clinical symptoms of depression and anxiety ...

MIRA Pharmaceuticals unveils Ketamir-2 topical for neuropathic pain, complementing its oral version. Clinical and preclinical ...

Depression and anxiety affect approximately 40% of adults with chronic pain, according to a massive new systematic review and ...

The Company is planning to announce interim data from its ongoing Halneuron ® Phase 2b chemotherapy induced neuropathic pain (“CINP”) trial in Q4 2025 ATLANTA, March (GLOBE NEWSWIRE) -- Dogwood ...

Fast track was first introduced by FDA to expedite development and review of drugs to treat serious conditions lacking any FDA-approved drug,” commented Gary S. Jacob, Ph.D., Chief Executive Officer ...